A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
Public ClinicalTrials.gov record NCT01900652. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to evaluate the efficacy of the study drug known as LY2875358, administered alone or in combination with a second drug named Erlotinib, in participants affected by a defined type of lung cancer (MET biomarker diagnostic positive Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent treatment with Erlotinib.
Study identification
- NCT ID
- NCT01900652
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2013 (Type not available)
- Primary completion
- Feb 2015 (Actual)
- Completion
- Mar 2016 (Actual)
- Last update posted
- Sep 18, 2019
2013 – 2016
United States locations
- U.S. sites
- 32
- U.S. states
- 21
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| University of California - San Diego | La Jolla | California | 92037 | — |
| For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Los Angeles | California | 90048 | — |
| University of California, Davis - Health Systems | Sacramento | California | 95817 | — |
| UCLA | Santa Monica | California | 90404 | — |
| University of Colorado Health Sciences Center | Aurora | Colorado | 80045 | — |
| Georgetown University Medical Center IRB | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916-2233 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| H Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northeast Georgia Cancer Care, LLC | Athens | Georgia | 30607 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| University of Iowa Hospital | Iowa City | Iowa | 52242 | — |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University Medical Center | St Louis | Missouri | 63110 | — |
| Billings Clinic Research Center | Billings | Montana | 59101 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| Columbia University | New York | New York | 10032 | — |
| Carolinas Medical Center | Charlotte | North Carolina | 28204 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Portland VA Medical Center | Portland | Oregon | 97213 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Tennessee Oncology PLLC | Chattanooga | Tennessee | 37404 | — |
| The West Clinic | Memphis | Tennessee | 38120 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| MS Center at Evergreen | Kirkland | Washington | 98034 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
| Group Health | Seattle | Washington | 98112 | — |
| Multicare Health System | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01900652, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 18, 2019 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01900652 live on ClinicalTrials.gov.